Pharvaris (PHVS) Consolidated Net Income (2025 - 2026)
Pharvaris posted quarterly Consolidated Net Income of -$45.6 million for Q1 2026, up 5.89% year-on-year from -$43.0 million in Q1 2025, and up 5.89% on a QoQ basis from -$48.4 million in Q1 2025.
Pharvaris (PHVS) has 2 years of Consolidated Net Income data on file, last reported at -$45.6 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 5.89% year-over-year to -$45.6 million; the trailing twelve-month figure through Mar 2026 stood at -$94.0 million (down 94.11% YoY), and the FY2025 full-year result was -$198.5 million, down 36.64% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$45.6 million, up from -$48.4 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$45.6 million in Q1 2026 and bottomed at -$48.4 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | -45.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.57 Mn |
| Mar 31, 2025 | -48.43 Mn |